AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
AngioDynamics received FDA IDE approval to initiate the RELIEF feasibility study, evaluating its NanoKnife System for treating benign prostatic hyperplasia (BPH). The single-arm study will enroll 40 subjects across up to five U.S. sites, focusing on safety and effectiveness endpoints over a five-year follow-up period.
Key figures
- Subjects
- 40
- Bph prevalence
- 15 million
- Clinical sites
- 5
- Annual surgical procedures
- 300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.